This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CDTX Cidara Therapeutics (CDTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Cidara Therapeutics Stock (NASDAQ:CDTX) Get Cidara Therapeutics alerts:Sign Up Key Stats Today's Range$221.25▼$221.4150-Day Range$219.60▼$221.3852-Week Range$18.51▼$221.42Volume2.69 million shsAverage Volume928,762 shsMarket Capitalization$6.96 billionP/E RatioN/ADividend YieldN/APrice Target$140.00Consensus RatingHold Company Overview Cidara Therapeutics, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of long‐acting anti‐infectives and immunotherapies to address life‐threatening fungal, viral and bacterial infections. The company’s core technology platforms, including its proprietary CD‐MONT and Cloudbreak platforms, are designed to create novel therapeutic candidates with extended half‐lives and differentiated mechanisms of action. By leveraging its expertise in macromolecular conjugates and immunotherapeutic design, Cidara seeks to offer new treatment options that can reduce dosing frequency and improve patient outcomes in critical care settings. The company’s lead asset, rezafungin, is a once‐weekly intravenous echinocandin antifungal in late‐stage development for the prevention and treatment of invasive candidiasis and other serious fungal infections. Rezafungin has been granted Fast Track designation by the U.S. Food and Drug Administration, and Cidara has entered into strategic licensing agreements to support its global commercialization. In addition to rezafungin, Cidara is advancing multiple Cloudbreak immunotherapeutic candidates aimed at combating respiratory viral pathogens, including RSV and coronaviruses, by stimulating the host immune system to mount long‐lasting responses. Cidara was founded in 2015 and is headquartered in San Diego, California. The company was established by a team of life science entrepreneurs and researchers with deep experience in drug discovery and development. Under the leadership of President and Chief Executive Officer Jeff Stein, Cidara has built a disciplined clinical development strategy and forged collaborative partnerships to accelerate its pipelines through late‐stage trials and regulatory review. Through collaborations and licensing agreements, Cidara serves markets in North America, Europe and other global territories. The company’s strategic alliances with pharmaceutical partners aim to expand access to its novel anti‐infective and immunotherapy candidates, addressing significant unmet medical needs in immunocompromised and critically ill patient populations.AI Generated. May Contain Errors. Read More Cidara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreCDTX MarketRank™: 0.10749902862 of 5 starsCidara Therapeutics scored higher than 2% of companies evaluated by MarketBeat, and ranked 901st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingCidara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and no sell ratings.Downside RiskCidara Therapeutics has a consensus price target of $140.00, representing about 36.8% downside from its current price of $221.38.Amount of Analyst CoverageCidara Therapeutics has received no research coverage in the past 90 days.Read more about Cidara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cidara Therapeutics are expected to decrease in the coming year, from ($8.74) to ($14.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -18.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -18.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCidara Therapeutics has a P/B Ratio of 14.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CDTX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest1 people have searched for CDTX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.89% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by Institutions35.82% of the stock of Cidara Therapeutics is held by institutions.Read more about Cidara Therapeutics' insider trading history. Receive CDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CDTX Stock News HeadlinesCidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion MergerJanuary 2, 2026 | msn.comIs Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?January 2, 2026 | fool.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 27 at 1:00 AM | Banyan Hill Publishing (Ad)Cidara: Merck's Acquisition Based On CD388 Flu Prevention PotentialDecember 29, 2025 | seekingalpha.comCidara Therapeutics (CDTX): Assessing Valuation After a 200% Three‑Month Share Price SurgeDecember 18, 2025 | finance.yahoo.comCidara Therapeutics (CDTX) price target increased by 18.53% to 220.19December 6, 2025 | msn.comCidara Therapeutics (CDTX): Assessing Valuation After a 137% One-Month SurgeNovember 25, 2025 | finance.yahoo.comCidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk PopulationsNovember 24, 2025 | globenewswire.comSee More Headlines CDTX Stock Analysis - Frequently Asked Questions How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics, Inc. (NASDAQ:CDTX) issued its earnings results on Thursday, November, 6th. The biotechnology company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by $0.24. Read the conference call transcript. When did Cidara Therapeutics' stock split? Cidara Therapeutics's stock reverse split on Wednesday, April 24th 2024.The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cidara Therapeutics IPO? Cidara Therapeutics (CDTX) raised $72 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,800,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include NVIDIA (NVDA), Iovance Biotherapeutics (IOVA), NIO (NIO), Tesla (TSLA), Advanced Micro Devices (AMD), ADMA Biologics (ADMA) and VBI Vaccines (VBIV). Company Calendar Last Earnings11/06/2025Today10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (22m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CDTX's financial health is in the Green zone, according to TradeSmith. CDTX has been in this zone for over 22 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CDTX CIK1610618 Webwww.cidara.com Phone(858) 752-6170FaxN/AEmployees90Year Founded2013Price Target and Rating Average Price Target for Cidara Therapeutics$140.00 High Price Target$145.00 Low Price Target$135.00 Potential Upside/Downside-36.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($11.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$169.83 million Net MarginsN/A Pretax MarginN/A Return on Equity-45.52% Return on Assets-38.31% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio4.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.92 per share Price / Book14.84Miscellaneous Outstanding Shares31,439,000Free Float30,216,000Market Cap$6.96 billion OptionableNo Data Beta1.52 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CDTX) was last updated on 1/7/2026 by MarketBeat.com Staff. From Our PartnersTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredBig Gains on Tap as Sub-US$1 Silver-Gold Discovery Takes ShapeA small-cap North American silver-gold explorer has unified a historic, fragmented mining district under one o...Resource Stock Digest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
